0.8 ML nedosiran 160 MG/ML Prefilled Syringe
- RxCUI
- 2675312
- RxNorm name
- 0.8 ML nedosiran 160 MG/ML Prefilled Syringe
- Display name
- 0.8 ML nedosiran 160 MG/ML Prefilled Syringe
- Full name
- 0.8 ML nedosiran 160 MG/ML Prefilled Syringe
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:15
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| RIVFLOZA | NEDOSIRAN | Novo Nordisk | ace9d4bc-4d20-4beb-9e9d-888690424833 | 2025-03-03 | Adverse reactions | 2675312 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| ace9d4bc-4d20-4beb-9e9d-888690424833 | nedosiran 128 MG in 0.8 ML Prefilled Syringe [PSN] · 0.8 ML nedosiran 160 MG/ML Prefilled Syringe [SCD] · nedosiran 128 MG (as nedosiran sodium 136 MG) per 0.8 ML Prefilled Syringe [SY] | 3 | 4 | These highlights do not include all the information needed to use RIVFLOZA safely and effectively. See full prescribing information for RIVFLOZA. RIVFLOZA ® (nedosiran) injection, for subcutaneous use Initial U.S. Approval: 2023 | 20250303 |